Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a medical device company that develops, manufactures and markets innovative products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Our primary product, the NxStage System One, or System One, was designed to satisfy an unmet clinical need for a system that can deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis clinics. Given its design, the System One is particularly well-suited for home hemodialysis and a range of dialysis therapies including more frequent dialysis, which clinical literature suggests provides patients better clinical outcomes and improved quality of life. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.26 |
| Quarterly EPS Est: | -0.07 |
| PEG Ratio: | -2.74 |
|
Mean Recommendation: View Summary / View All |
1.78 |
Data is provided by Zacks Investment Research

